Zimmer Biomet (ZBH) Asia Pacific chief adds shares through RSU grants

Rhea-AI Filing Summary

Zimmer Biomet Holdings executive Yi Sang reported equity awards and conversions, increasing his direct holdings through stock-based compensation. He acquired 2,382 shares of common stock on February 20, 2026 via exercise or conversion of restricted stock units (RSUs) at $0.00 per share, bringing his direct common stock ownership to 20,052 shares.

On the same date, he also acquired 2,382 RSUs through an exercise or conversion and received a new grant of 9,043 RSUs. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and vests annually over three years in one-third increments starting on February 20, 2027.

Insider Trade Summary

2,382 shares exercised/converted

Mixed 3 txns

Insider Yi Sang

Role Group President, Asia Pacific

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,382	$0.00	--
Grant/Award	Restricted Stock Units	9,043	$0.00	--
Exercise	Common Stock	2,382	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,382 shares (Direct); Common Stock — 20,052 shares (Direct)

Footnotes (1)

1. Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. Vests annually over three years in increments of one-third each year, commencing February 20, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		2,382	A	$0	20,052	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/20/2026		M			2,382	02/20/2026	02/20/2026	Common Stock	2,382	$0	2,382	D
Restricted Stock Units	(1)	02/20/2026		A		9,043		(2)	(2)	Common Stock	9,043	$0	9,043	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

2. Vests annually over three years in increments of one-third each year, commencing February 20, 2027.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Yi Sang report at ZIMMER BIOMET HOLDINGS, INC. (ZBH)?

Yi Sang reported equity-based acquisitions on February 20, 2026, including 2,382 common shares received from RSU exercise and additional RSU-related awards. These transactions reflect compensation-related movements rather than open-market buying or selling activity by the Zimmer Biomet Group President, Asia Pacific.

How many ZIMMER BIOMET (ZBH) common shares does Yi Sang own after this Form 4?

After the reported transactions, Yi Sang directly holds 20,052 shares of Zimmer Biomet common stock. This figure reflects the addition of 2,382 common shares received through the exercise or conversion of restricted stock units disclosed as of February 20, 2026, in the Form 4 filing.

What restricted stock unit (RSU) grants did Yi Sang receive from ZIMMER BIOMET (ZBH)?

Yi Sang received a grant of 9,043 restricted stock units, each representing a contingent right to one Zimmer Biomet common share. These RSUs vest over three years in equal one-third annual installments, beginning on February 20, 2027, as part of his equity-based compensation.

How do Yi Sang’s RSUs at ZIMMER BIOMET (ZBH) vest over time?

The RSUs vest annually over three years in one-third increments. The vesting schedule begins on February 20, 2027, meaning one-third of the 9,043 RSUs becomes deliverable each year, subject to the award’s terms, gradually converting into Zimmer Biomet common stock.

Were there any open-market stock purchases or sales by Yi Sang in this ZBH Form 4?

The reported transactions involve RSU exercises and grants with a per-share transaction price of $0.00, indicating compensation-related equity movements. There are no disclosed open-market purchases or sales; all activity is tied to derivative security exercises and awards of restricted stock units.

What does each RSU reported by Yi Sang at ZIMMER BIOMET (ZBH) represent?

Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet common stock. Delivery of shares occurs as units vest according to the three-year schedule, starting February 20, 2027, linking Yi Sang’s future share ownership to continued service and award conditions.